AUTHOR=Huang Jingjing , Ding Weize , Zhu Xingfan , Li Bingbing , Zeng Fangang , Wu Kui , Wu Xiaoqin , Wang Fuyi 

TITLE=Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs

JOURNAL=Frontiers in Chemistry

VOLUME=10

YEAR=2022

URL=https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2022.876410

DOI=10.3389/fchem.2022.876410

ISSN=2296-2646

ABSTRACT=<p>Photoactivatable Pt(IV) anticancer prodrugs with the structure of [Pt<sup>IV</sup>(N<sub>1</sub>)(N<sub>2</sub>)(L<sub>1</sub>)(L<sub>2</sub>)(A<sub>1</sub>)(A<sub>2</sub>)], where N<sub>1</sub> and N<sub>2</sub> are non-leaving nitrogen donor ligands, L<sub>1</sub> and L<sub>2</sub> are leaving ligands, and A<sub>1</sub> and A<sub>2</sub> are axial ligands, have attracted increasing attention due to their promising photo-cytotoxicity even to cisplatin-resistant cancer cells. These photochemotherapeutic prodrugs have high dark-stability under physiological conditions, while they can be activated by visible light restrained at the disease areas, as a consequence showing higher spatial and temporal controllability and much more safety than conventional chemotherapy. The coordinated ligands to the Pt center have been proved to be pivotal in determining the function and activity of the photoactivatable Pt(IV) prodrugs. In this review, we will focus on the development of the coordinated ligands in such Pt(IV) prodrugs and discuss the effects of diverse ligands on their photochemistry and photoactivity as well as the future evolution directions of the ligands. We hope this review can help to facilitate the design and development of novel photoactivatable Pt(IV) anticancer prodrugs.</p>